CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
UC's CECH recognizes students, faculty and staff for outstanding...
April 24, 2025
In the early weeks of April 2025, UC's College of Education, Criminal Justice, Human Services, and Information Technology recognized and celebrated students, faculty and staff achievements annual Outstanding Student Awards and All College Awards ceremony, the latter of which awarded both Faculty and Staff Awards and the college's Golden Apple Awards.
UC Blue Ash and UC Clermont earn national recognition for...
April 24, 2025
The University of Cincinnati’s regional colleges—UC Blue Ash and UC Clermont—have each received prestigious national recognition through the newly established Student Access and Earnings Classification, announced today by the Carnegie Foundation and the American Council on Education.
Small businesses may face the biggest challenges from tariffs
April 24, 2025
Gary Painter, PhD, academic director or real estate at Lindner, spoke with Spectrum News 1 on the impact large economic shifts can have on small businesses.